VERTEX PHARMACEUTICALS INC / MA Deferred Revenue Recognized
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Deferred Revenue Recognized of $206.80 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2026-02-13
- VERTEX PHARMACEUTICALS INC / MA contract with customer, liability, revenue recognized for the quarter ending 2018-03-31 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA contract with customer, liability, revenue recognized for fiscal 2025 was $206.80M, a 21.43% increase from fiscal 2024.
- VERTEX PHARMACEUTICALS INC / MA contract with customer, liability, revenue recognized for fiscal 2024 was $170.30M, a 6.70% increase from fiscal 2023.
- VERTEX PHARMACEUTICALS INC / MA contract with customer, liability, revenue recognized for fiscal 2023 was $159.60M, a 7.05% decline from fiscal 2022.
- VERTEX PHARMACEUTICALS INC / MA contract with customer, liability, revenue recognized for fiscal 2022 was $171.70M, a 10.34% decline from fiscal 2021.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2025-12-31 | $206.80M 10-K · filed 2026-02-13 | |||
| 2024-12-31 | $170.30M 10-K · filed 2026-02-13 | |||
| 2023-12-31 | $159.60M 10-K · filed 2026-02-13 | |||
| 2022-12-31 | $171.70M 10-K · filed 2025-02-13 | |||
| 2021-12-31 | $191.50M 10-K · filed 2024-02-15 | |||
| 2020-12-31 | $62.30M 10-K · filed 2023-02-10 | |||
| 2019-12-31 | $24.90M 10-K · filed 2022-02-09 | |||
| 2018-12-31 | $1.70M 10-K · filed 2021-02-11 | |||
| 2018-09-30 | $16.61M 10-Q · filed 2018-10-25 | |||
| 2018-06-30 | $3.74M 10-Q · filed 2018-07-26 | |||
| 2018-03-31 | $0.00 10-Q · filed 2018-04-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |